Home

Articles from Sequana Medical NV

Transparency Notifications from Shareholders
Transparency Notifications from Shareholders
By Sequana Medical NV · Via GlobeNewswire · February 3, 2025
Press release: Sequana Medical Announces New Share Capital Amount and New Number of Shares following Loan Conversions
SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT
By Sequana Medical NV · Via GlobeNewswire · January 24, 2025
Press release: Transparency Notification from Shareholders
Transparency Notification from Shareholders
By Sequana Medical NV · Via GlobeNewswire · January 13, 2025
Press release: Six Month Data from alfapump® Pivotal POSEIDON Study in Treatment of Recurrent or Refractory Ascites due to Liver Cirrhosis Published in American Journal of Gastroenterology
Six Month Data from alfapump® Pivotal POSEIDON Study in Treatment of Recurrent or Refractory Ascites due to Liver Cirrhosis Published in American Journal of Gastroenterology
By Sequana Medical NV · Via GlobeNewswire · January 7, 2025
Press release: Sequana Medical Announces Key Opinion Leader (KOL) Webinar to Discuss alfapump® US Commercial Roll-Out on January 8th at 15:00 CET / 09:00 EST
Sequana Medical Announces Key Opinion Leader (KOL) Webinar to Discuss alfapump® US Commercial Roll-Out on January 8th at 15:00 CET / 09:00 EST
By Sequana Medical NV · Via GlobeNewswire · January 6, 2025
Press release: Sequana Medical Announces US FDA Approval of alfapump® for the Treatment of Recurrent or Refractory Ascites due to Liver Cirrhosis
Sequana Medical Announces US FDA Approval of alfapump® for the Treatment of Recurrent or Refractory Ascites due to Liver Cirrhosis
By Sequana Medical NV · Via GlobeNewswire · December 23, 2024
Press Release: Sequana Medical Announces Strong 24-Month Results from POSEIDON Study at AASLD The Liver Meeting® in San Diego; US PMA alfapump approval expected before end of Q1 2025
Sequana Medical Announces Strong 24-Month Results from POSEIDON Study at AASLD The Liver Meeting® in San Diego; US PMA alfapump approval expected before end of Q1 2025
By Sequana Medical NV · Via GlobeNewswire · November 18, 2024
Sequana Medical announces data on alfapump® safety and quality of life to be presented at EASL Congress 2024
Sequana Medical announces data on alfapump® safety and quality of life to be presented at EASL Congress 2024
By Sequana Medical NV · Via GlobeNewswire · June 6, 2024
Press news: Sequana Medical announces positive outcome of Day 100 meeting with FDA regarding PMA application for alfapump®
PRESS RELEASE: REGULATED INFORMATION – INSIDE INFORMATION 22 MAY 2024, 07:00 CEST
By Sequana Medical NV · Via GlobeNewswire · May 22, 2024
Transparency Notifications from Shareholders
PRESS RELEASEREGULATED INFORMATION3 April 2024, 06:00 pm CEST
By Sequana Medical NV · Via GlobeNewswire · April 3, 2024
Strong data from DSR® proof-of-concept studies in heart failure published in European Journal of Heart Failure
By Sequana Medical NV · Via GlobeNewswire · April 3, 2024
Sequana Medical announces 2023 Full Year Results and 2024 Outlook
PRESS RELEASEREGULATED INFORMATION – INSIDE INFORMATION28 March 2024, 08:00 a.m. CET
By Sequana Medical NV · Via GlobeNewswire · March 28, 2024
SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES
By Sequana Medical NV · Via GlobeNewswire · March 26, 2024
Sequana Medical announces three month follow-up data from MOJAVE non-randomized cohort confirming dramatic improvement in diuretic response and virtual elimination of loop diuretics following DSR® therapy
By Sequana Medical NV · Via GlobeNewswire · March 25, 2024
Strong data from DSR® proof-of-concept studies in heart failure accepted for late-breaking presentation at THT 2024
Presentation by Key Opinion Leader Dr. Testani on Wednesday, March 6th 2024
By Sequana Medical NV · Via GlobeNewswire · February 28, 2024
Sequana Medical announces FDA acceptance for substantive review of the Premarket Approval application for alfapump® in recurrent or refractory ascites due to liver cirrhosis
PRESS RELEASE
By Sequana Medical NV · Via GlobeNewswire · January 29, 2024
Transparency Notifications from Shareholders
By Sequana Medical NV · Via GlobeNewswire · January 24, 2024
Sequana Medical announces DSMB approval to start randomized MOJAVE cohort – US Phase 1/2a study of DSR® 2.0 for treatment of heart failure
PRESS RELEASEREGULATED INFORMATION – INSIDE INFORMATION23 January 2024, 07:00 am CET
By Sequana Medical NV · Via GlobeNewswire · January 23, 2024
Transparency Notifications from Shareholders
PRESS RELEASEREGULATED INFORMATION
By Sequana Medical NV · Via GlobeNewswire · January 15, 2024
Sequana Medical granted US CPT® III reimbursement codes for alfapump® system
PRESS RELEASE
By Sequana Medical NV · Via GlobeNewswire · January 3, 2024
Sequana Medical submits Premarket Approval application to US FDA for alfapump® in recurrent or refractory ascites due to liver cirrhosis
By Sequana Medical NV · Via GlobeNewswire · December 28, 2023
Sequana Medical announces positive data from non-randomized cohort in US Phase 1/2a MOJAVE study of DSR® 2.0 for treatment of heart failure
 
By Sequana Medical NV · Via GlobeNewswire · November 29, 2023
Sequana Medical announces results of Extraordinary General Meeting of Shareholders
PRESS RELEASEREGULATED INFORMATION10 November 2023, 06:00 pm CET
By Sequana Medical NV · Via GlobeNewswire · November 10, 2023
Sequana Medical announces additional alfapump data supporting strong and durable clinical profile; PMA on track for year-end submission
PRESS RELEASEREGULATED INFORMATION – INSIDE INFORMATION19 October 2023, 07:00 am CEST
By Sequana Medical NV · Via GlobeNewswire · October 19, 2023
Sequana Medical announces initial positive data from MOJAVE, a US Phase 1/2a study of DSR® 2.0 for treatment of heart failure through breaking vicious cycle of cardiorenal syndrome
PRESS RELEASEREGULATED INFORMATION – INSIDE INFORMATION18 October 2023, 07:00 am CEST
By Sequana Medical NV · Via GlobeNewswire · October 18, 2023
Sequana Medical announces H1 2023 results and provides business update
PRESS RELEASEREGULATED INFORMATION – INSIDE INFORMATION14 September 2023, 07:00 CEST
By Sequana Medical NV · Via GlobeNewswire · September 14, 2023
Sequana Medical Notice of 2023 Half-year Results and Business Update
By Sequana Medical NV · Via GlobeNewswire · September 6, 2023
Sequana Medical announces first patient enrolled in MOJAVE, a US randomized controlled Phase 1/2a study of DSR® 2.0 for treatment of congestive heart failure
PRESS RELEASE
By Sequana Medical NV · Via GlobeNewswire · July 10, 2023
1,000th alfapump® implant completed
 
By Sequana Medical NV · Via GlobeNewswire · July 6, 2023
Sequana Medical announces results of Special General Meeting of Shareholders
PRESS RELEASEREGULATED INFORMATION26 June 2023, 06:00 pm CEST
By Sequana Medical NV · Via GlobeNewswire · June 26, 2023
Sequana Medical announces additional data on safety, quality of life and survival from North American pivotal alfapump® study (POSEIDON)
PRESS RELEASEREGULATED INFORMATION – INSIDE INFORMATION21 June 2023, 07:00 am CEST
By Sequana Medical NV · Via GlobeNewswire · June 21, 2023
Additional data from North American pivotal alfapump® study (POSEIDON) will be presented at EASL Congress 2023
PRESS RELEASE
By Sequana Medical NV · Via GlobeNewswire · June 19, 2023
Sequana Medical wins Best Technology Award for alfapump® at European Mediscience Awards
By Sequana Medical NV · Via GlobeNewswire · June 16, 2023
Sequana Medical announces Special General Meeting of Shareholders on 26 June 2023
PRESS RELEASEREGULATED INFORMATION26 May 2023, 07:00 am CEST
By Sequana Medical NV · Via GlobeNewswire · May 26, 2023
Sequana Medical announces results of Annual General Meeting of Shareholders
PRESS RELEASEREGULATED INFORMATION25 May 2023, 06:00 pm CEST
By Sequana Medical NV · Via GlobeNewswire · May 25, 2023
Transparency Notifications from Shareholders
PRESS RELEASEREGULATED INFORMATION
By Sequana Medical NV · Via GlobeNewswire · May 15, 2023
SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES
PRESS RELEASEREGULATED INFORMATION10 May 2023, 06:00 p.m. CEST
By Sequana Medical NV · Via GlobeNewswire · May 10, 2023
Sequana Medical announces FDA clearance of IND application for DSR® 2.0 for treatment of congestive heart failure
PRESS RELEASE
By Sequana Medical NV · Via GlobeNewswire · May 2, 2023
SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES
PRESS RELEASEREGULATED INFORMATION27 April 2023, 07:00 p.m. CEST
By Sequana Medical NV · Via GlobeNewswire · April 27, 2023
Sequana Medical announces submission of Investigational New Drug (IND) application for DSR® 2.0 for treatment of congestive heart failure
PRESS RELEASE
By Sequana Medical NV · Via GlobeNewswire · April 3, 2023
Sequana Medical announces additional patents for DSR® in China and the United States
PRESS RELEASE
By Sequana Medical NV · Via GlobeNewswire · March 22, 2023
Sequana Medical announces positive results from CHIHUAHUA, Phase 1 clinical trial of second-generation DSR product for congestive heart failure
PRESS RELEASE
By Sequana Medical NV · Via GlobeNewswire · March 1, 2023
Sequana Medical announces results of Extraordinary General Meeting of Shareholders
PRESS RELEASEREGULATED INFORMATION10 February 2023, 18:00 CET
By Sequana Medical NV · Via GlobeNewswire · February 10, 2023
Sequana Medical announces 2022 Full Year Results and 2023 Outlook
PRESS RELEASEREGULATED INFORMATION09 February 2023, 07:00 CEST
By Sequana Medical NV · Via GlobeNewswire · February 9, 2023
Transparency Notifications from Shareholders
PRESS RELEASEREGULATED INFORMATION09 February 2023, 07:00 am CEST
By Sequana Medical NV · Via GlobeNewswire · February 9, 2023
Sequana Medical announces the successful completion of pre-clinical studies with its second-generation DSR product for congestive heart failure
PRESS RELEASE
By Sequana Medical NV · Via GlobeNewswire · February 8, 2023
Sequana Medical Notice of 2022 Full Year Results and Business Update
PRESS RELEASE
By Sequana Medical NV · Via GlobeNewswire · February 2, 2023
Sequana Medical announces grant of additional DSR® patent in United States
PRESS RELEASE
By Sequana Medical NV · Via GlobeNewswire · February 1, 2023
Sequana Medical announces Extraordinary General Meeting of Shareholders on 10 February 2023
PRESS RELEASEREGULATED INFORMATION11 January 2023, 07:00 am CEST
By Sequana Medical NV · Via GlobeNewswire · January 11, 2023
Sequana Medical announces positive top-line results from SAHARA Ph. 2a study of DSR 1.0 in diuretic-resistant heart failure patients with persistent congestion and first patient dosed successfully with DSR 2.0 in YUKON
PRESS RELEASEREGULATED INFORMATION – INSIDE INFORMATION15 November 2022, 07:00 am CET
By Sequana Medical NV · Via GlobeNewswire · November 15, 2022
Sequana Medical to present at Jefferies London Healthcare Conference
By Sequana Medical NV · Via GlobeNewswire · November 8, 2022
Sequana Medical announces positive top-line results from the North American pivotal alfapump® study (POSEIDON)
PRESS RELEASEREGULATED INFORMATION – INSIDE INFORMATION25 October 2022, 07:00 am CET
By Sequana Medical NV · Via GlobeNewswire · October 25, 2022
Data from Roll-In Cohort of North American pivotal alfapump® study (POSEIDON) selected for poster presentation at AASLD The Liver Meeting®
By Sequana Medical NV · Via GlobeNewswire · October 21, 2022